P/E Ratio

The P/E ratio of 41.4x means investors are paying $41.40 for every $1 of Eli Lilly’s earnings over the past year, reflecting the premium they are willing to pay for expected future growth.

This level is well above the healthcare sector median of 27.6x, placing Lilly in the 79th percentile among its peers, indicating it is more expensive than most comparable companies. Over the last eight quarters the trend has been stable, with a year-over-year increase of +9.7% and a quarter-over-quarter increase of +6.4%. The combination of a high P/E and a stable upward trend suggests that investor expectations for earnings growth remain elevated, creating potential downside risk if growth slows, but also opportunity if the company meets those expectations. This metric supports the overall NEUTRAL verdict, as the elevated valuation relative to peers is balanced by a steady trend that does not signal immediate overvaluation or a clear bargain.

Frequently Asked Questions

Closest Sector Peers